Aprea Therapeutics (NASDAQ:APRE) Upgraded at Zacks Research

Zacks Research upgraded shares of Aprea Therapeutics (NASDAQ:APRE) from a strong sell rating to a hold rating in a research note released on Monday morning,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on the company. Wedbush dropped their price objective on Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating for the company in a research note on Tuesday, February 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target (down previously from $5.00) on shares of Aprea Therapeutics in a research note on Thursday, January 29th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Aprea Therapeutics currently has an average rating of “Hold” and an average target price of $5.50.

Aprea Therapeutics Price Performance

Shares of APRE stock opened at $0.73 on Monday. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $3.57. The firm has a market capitalization of $5.09 million, a PE ratio of -0.34 and a beta of 1.48. The business’s fifty day moving average price is $0.82 and its 200 day moving average price is $1.22.

Insider Activity

In related news, Director Marc Duey acquired 21,459 shares of the company’s stock in a transaction that occurred on Wednesday, December 10th. The stock was purchased at an average price of $1.17 per share, for a total transaction of $25,107.03. Following the transaction, the director owned 256,155 shares in the company, valued at $299,701.35. This trade represents a 9.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 13.63% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.67% of Aprea Therapeutics at the end of the most recent reporting period. Institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.